Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)
Public ClinicalTrials.gov record NCT05858879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Estimate the impact of notifying both patients and their clinicians of the presence of incidental coronary artery calcium (CAC) on initiation of lipid-lowering therapy in patients with ASCVD who are not receiving lipid-lowering therapy.
Study identification
- NCT ID
- NCT05858879
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 233 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 84 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2024
- Primary completion
- Mar 23, 2026
- Completion
- Mar 23, 2026
- Last update posted
- Apr 21, 2026
2024 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Stanford | California | 94304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated ASCVD trials
Other public records listing ASCVD. Sorted by last update posted; newest first. Not a recommendation.
- NCT05611307: Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors Recruiting
- NCT07417618: INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) Active, not recruiting
- NCT06691217: Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis Recruiting
- NCT07303777: Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis Recruiting
- NCT07522645: Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease Not yet recruiting
- NCT05390892: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05858879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05858879 live on ClinicalTrials.gov.